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Abstract
Background—The early visual-evoked gamma oscillation (VGO) elicited by Gestalt stimuli is
reduced in schizophrenia patients compared to healthy individuals, but it is unknown whether this
effect is specific to these particular stimuli and task. In contrast, the early auditory-evoked gamma
oscillation (AGO) was reported to be unaffected in a sample of unmedicated, mostly first-episode
schizophrenics (Gallinat et al, 2004, Clin Neurophysiol), but it is unknown whether this oscillation
is abnormal in chronic, medicated patients. We investigated these issues by examining the VGO and
AGO in chronic schizophrenics (SZ) and matched healthy controls (HC).
Methods—Subjects (21 HC, 23 SZ) performed visual and auditory oddball tasks. Visual stimuli
were letters, and auditory stimuli were simple tones. Event-related spectral measures (phase locking
factor and evoked power) were computed on Morlet wavelet-transformed single epochs from the
standard trials.
Results—VGO phase locking at occipital electrodes was reduced in SZ compared to HC. In
contrast, AGO phase locking and evoked power did not differ between groups.
Conclusions—The VGO deficit may be a general phenomenon in schizophrenia, while the AGO
evoked by simple tone stimuli does not appear to be abnormal in chronic, medicated schizophrenics.
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Oscillatory neuronal synchronization in the gamma band (~30–100 Hz) of the
electroencephalogram (EEG) has been proposed to play an important role in neural information
coding (1). Gamma abnormalities have been hypothesized to reflect core neural circuit
abnormalities and cognitive deficits in schizophrenia (2–7). Among the gamma oscillations
reported in humans, the most reliably found are the early sensory-evoked oscillations (8). The
visual-evoked gamma oscillation (VGO) occurs at 25–45 Hz and ~100 ms and is sensitive to
attentional and perceptual factors (9). The auditory-evoked gamma oscillation (AGO) occurs
at 30–60 Hz and ~50 ms and is also sensitive to attentional factors (10).
Previously we reported that VGO phase locking was reduced in chronic schizophrenia patients
compared to healthy individuals in a Gestalt perception task (6,11), consistent with
electrophysiological and behavioral observations of dysfunctional early visual processing in
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schizophrenia (e.g., 12–15). However, it is unclear whether this deficit is specific to that
particular task and/or stimuli, or occurs generally for visual stimuli independently of the task.
In contrast, Gallinat et al. (16) observed no abnormalities of the AGO in schizophrenics, which
is surprising since abnormalities of auditory cortex and early auditory processes have been
consistently reported in schizophrenia (e.g., 17–19). Since Gallinat et al. examined only
unmedicated patients, most of whom were first-episode, it is possible that an AGO deficit
would be apparent in chronic, medicated schizophrenics.
Here we sought to determine whether: 1) the VGO deficit in schizophrenia is specific to the
Gestalt perception task used previously, or can be found with other stimuli and tasks; and 2)
the AGO is abnormal in chronic, medicated schizophrenics.
Method
Subjects
The study was approved by the Institutional Review Boards of the VA Boston Healthcare
System and Harvard Medical School. Informed consent was obtained from all subjects, who
were paid for their participation. Subjects (all male) were 21 healthy controls (HC) and 23
chronic schizophrenia patients (SZ). HC were recruited from the community and were free of
Axis I or II disorders (20,21), as well as a history of Axis I disorders in first-degree relatives.
SZ were diagnosed with schizophrenia according to DSM-IV criteria (22). Subjects were
selected without regard for ethnicity and met our standard inclusion/exclusion criteria: 1) right-
handed (23); 2) no history of electroconvulsive treatment or neurological illness; 3) no alcohol
or drug dependence within the last 5 years (DSM-IV criteria); 4) no present medication for
medical disorders that would have deleterious EEG, neurological, or cognitive consequences;
and 5) estimated verbal IQ above 75.
Demographic and clinical data and inter-group comparisons are summarized in the Table. All
patients received atypical antipsychotics. None of the electrophysiological measures were
correlated with antipsychotic dosage (2-tailed Spearman’s ρ < 0.252, p > 0.299), calculated as
chlorpromazine equivalents (25,26).
Stimuli and Experimental Design
Subjects performed oddball tasks in which they counted rare target stimuli (30/180 stimuli,
1200 ms stimulus onset asynchrony). In the Visual task, stimuli (2° height by 1.8° width) were
presented at central fixation in white on a black background for 100 ms. Targets and standards
were the letters “X” and “Y”, respectively. In the Auditory task, tones (70 ms duration, 10 ms
rise/fall) were presented through headphones (70 dB sound pressure level) while subjects
fixated a cross in the center of the monitor. The target and standard tone frequencies were 1200
and 1000 Hz, respectively. Task order was counterbalanced across subjects.
Electrophysiological Recording and Analysis
The EEG was recorded (0.01-100 Hz, 500 Hz digitization) with sintered Ag/Ag-Cl electrodes
in an electrode cap at 60 scalp sites, nosetip, and left earlobe, referenced to the right earlobe,
grounded at AFz. Bipolar vertical and horizontal electro-oculograms were recorded from
electrodes above and below the right eye and at the left and right outer canthi, respectively.
Electrode impedances were <10 kΩ. Single-trial epochs were extracted from −250 to 850 ms
relative to stimulus onset and corrected for eye movements and blinks (27). Epochs containing
artifacts were removed.
We examined the gamma oscillations evoked by standard stimuli, which were unconfounded
by target-related processing. The Morlet wavelet transform was applied to single epochs in 1
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Hz steps from 20–100 Hz and −250 to 772 ms. Event-related spectral measures were computed
on the wavelet-transformed epochs at each time point and wavelet frequency to yield time-
frequency maps (28). Phase locking factor (PLF) measures the variance of phase across single
trials, independent of power. PLF is computed as one minus the circular variance of phases
and ranges from 0 (random distribution) to 1 (perfect phase locking). Evoked power measures
the power of the average evoked potential, in which the contribution of non-stimulus-locked
activity is minimized. Average baseline values were subtracted from each time-frequency map
(−150 to 0 ms).
In ANOVAs the Greenhouse-Geisser correction for inhomogeneity of variance (29) was
applied for factors with more than 2 levels, and is reflected in the reported p values.
Further methodological details are given in the Supplementary Material.
Results
SZ and HC had highly accurate target counts in both oddball tasks (see Table). Evoked potential
data are presented in the Supplementary Material.
The VGO (Fig. 1A) was apparent in the PLF but not the evoked power data, as we reported
previously (6,11), so evoked power was not further analyzed. PLF was measured between 30–
38 Hz and 96–130 ms. The ANOVA design was Group X Hemisphere X Electrode. As
previously observed, the VGO had components at frontal and occipital electrode sites (30).
Occipital VGO PLF was measured at electrodes P1/2, PO1/2, PO7/8, and O1/2, and was
significantly reduced in SZ compared to HC (F[1,42] = 4.76, p < 0.05). Frontal VGO PLF was
measured at electrodes F1/2, F3/4, FC1/2, FC3/4, FC5/6, and C1/2, and did not differ between
groups (F[1,42] = 1.09, p = 0.303).
The AGO (Fig. 1B) was measured at fronto-central electrode sites (F1/2, F3/4, F5/6, FC1/2,
FC3/4, FC5/6, C1/2, C3/4, and C5/6) between 34–54 Hz, in the 30–74 ms range for HC and
38–82 ms for SZ. The ANOVA design was Group X Hemisphere X Midline (Frontal/Fronto-
central/Central) X Lateral Site (1/2, 3/4, 5/6). AGO PLF (F[1,42] = 0.404, p = 0.528) and
evoked power (F[1,42] = 0.398, p = 0.531) did not differ between SZ and HC.
Discussion
VGO phase locking evoked by standard stimuli in an oddball task was reduced in SZ.
Previously we reported that Gestalt stimuli evoked the VGO in healthy individuals but not in
chronic schizophrenia patients (6,11). One possible explanation was that this VGO deficit
reflected a specific failure of synchronization to Gestalt stimuli. The present results rule this
out because the stimulus used here was a letter.
Another explanation was that the VGO deficit reflected a failure of synchronization to “target-
like” stimuli, as the VGO can be influenced by the degree to which a particular stimulus matches
the target stimulus in a discrimination task (31). However, here the VGO was evoked in HC
by standard stimuli in an oddball task that were not associated with a manual response, rather
than target stimuli as in the Gestalt perception task. Thus, the VGO deficit has been found in
two different tasks for different stimuli with differing response requirements. These results
suggest that the VGO deficit may be a general phenomenon in schizophrenia, independent of
task and stimulus type.
The origin of the VGO deficit is not clear. One possibility is some neural circuitry abnormality
in visual cortex that prevents gamma-frequency synchronization from occurring. Another
possibility is deficient attentional modulation from the dorsolateral prefrontal cortex (DLPFC)
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(32). In healthy individuals the VGO is influenced by attentional demands (33) and target-
match effects (31,34), so the failure of an attentional signal to enhance neuronal
synchronization in visual cortex could impair the VGO. For instance, Barceló et al (35) found
that attention-sensitive visual evoked potentials were reduced over the hemisphere ipsilateral
to a DLPFC lesion. The VGO deficit could represent a similar failure of attentional modulation
of sensory processing, given the evidence of DLPFC neural circuitry abnormalities (4,36,37)
and attentional dysfunction (38) in schizophrenia.
The AGO was not abnormal in SZ, consistent with the finding of Gallinat et al. (16) that AGO
evoked power did not differ between healthy individuals and unmedicated, mainly first-episode
schizophrenics. Here the patients were chronic and medicated, so together these studies suggest
that the AGO is generally not affected in schizophrenia. (Nor was an auditory N1 deficit found;
see Supplementary Material.) The absence of an AGO deficit is surprising given the abundance
of structural and functional abnormalities of the auditory system in schizophrenia (17–19),
especially since the gamma-band auditory steady-state response is reduced in schizophrenia
(39–41). But since our study and that of Gallinat et al. used oddball tasks with simple tone
stimuli, it remains to be determined whether the absence of an AGO deficit is specific to this
particular type of task and/or stimuli.
While none of the electrophysiological measures was correlated with antipsychotic medication
dosage, possible influences of medication cannot be ruled out, given the inexact nature of
chlorpromazine equivalency and the complex effects of atypical antipsychotics on neural
activity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The visual- and auditory-evoked gamma oscillations (VGO/AGO) in healthy controls (HC)
and chronic schizophrenia patients (SZ). (A) Visual data: Phase locking factor (PLF) and
evoked power time-frequency maps at electrode O1 (left) and topographic maps of VGO PLF
(right). The occipital VGO is present in HC but not SZ. (B) Auditory data: PLF and evoked
power time-frequency maps at electrode Fz (left) and topographic maps of AGO PLF (right).
There were no significant overall differences in either measure of the AGO between HC and
SZ.
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Table
Comparison of demographic and clinical variables for the HC and SZ groups. Mean +/− standard deviation are
given for each variable.
HC SZ Statistic p
Age (years) 42.2 +/− 9.4 40.7 +/− 10.6 F[1,42] = 0.245 0.623
Parental socioeconomic status (ref. 24) 2.8 +/− 1.3 2.7 +/− 1.2 F[1,38] = 0.143 0.707
Handedness 0.75 +/− 0.17 0.72 +/− 0.24 F[1,42] = 0.180 0.674
Age of onset (years) 22.6 +/− 5.8
Medication dosage 340 +/− 267
(CPZ equivalents) range 0–900
Target count: visual 29.7 +/− 3.4 29.3 +/− 1.6 F[1,42] = 0.261 0.612
Target count: auditory 30.4 +/− 1.6 29.6 +/− 2.4 F[1,42] = 1.72 0.197
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